Skip to content Skip to footer

Emerging Solutions in the Battle Against RSV: Monoclonal Antibody and Vaccine Interventions

Last year, Victoria Spain Robinson witnessed firsthand the impact of respiratory syncytial virus (RSV), a notorious yet under-recognized ailment, when her godson, Kristopher Head, fought the virus. Today, Louisiana, among several southeastern states which are witnessing an unexpected RSV season, is leading the way in prevention strategies, armed with advanced tools that could change the disease landscape significantly — a monoclonal antibody for younger children and a vaccine intended for individuals aged 60 and above, pregnant women, and their infants.

Dr. Mark Kline, physician in chief at Children’s Hospital New Orleans, encapsulates the optimism, celebrating these new tools as ‘a remarkable advance.’ RSV prompts typical cold symptoms in most people but can prove dangerous, even fatal, for vulnerable groups such as newborns, individuals with heart conditions or chronic lung disease, and the elderly. It is the chief cause of infant hospitalizations, accounting for roughly 80,000 hospital stays annually and claiming the lives of around 300 children under five every year.

Memories of severe RSV cases flooding pediatric hospitals in Louisiana in 2021 and 2022 remain vivid, underlying the urgent necessity for effective interventions. Recent state health data revealed a positivity rate of around 14% last week for RSV tests conducted at Children’s Hospital, up from approximately 6% the previous week. To tackle the increasing incidence of positive RSV cases, the Centers for Disease Control and Prevention (CDC) has recently recommended a dosage of monoclonal antibodies for infants below eight months entering their first RSV season.

Manufactured by AstraZeneca and Sanofi, the drug referred to as nirsevimab or Beyfortus is intended to ward off severe RSV disease confirmed to be about 80% effective in avoiding hospitalizations. It is important to note that this is not a vaccine; it does not induce the body to create its own antibodies in reaction to a small quantity of virus-like substance introduced. Instead, protection is directly injected. This therapeutic intervention should be available starting early October as stated by the CDC. The potential side effects include mild reactions such as rashes and reactions at the injection site.

Additionally, a vaccine shot given during pregnancy to safeguard infants from RSV, named Abrysvo and produced by Pfizer, is expected to be available soon. It showed 82% efficacy in preventing severe disease in infants during the initial three months post-birth, and 69% protection six months thereafter.

Concurrently, an RSV vaccine for adults over 60 years of age has been approved, given the potential risk of hospitalization and death from RSV in this age group. Health officials advocate for a risk-benefit discussion between patients and their healthcare providers considering the vaccination due to rare but serious side effects documented during trials.


Sign Up to Our Newsletter

Be the first to know the latest updates

[yikes-mailchimp form="1"]